CHICAGO , June 26, 2024 /PRNewswire/ -- The urinalysis market , valued at USD 4.3 billion in 2024 and projected to grow to USD 6.8 billion by 2029 with a CAGR of 9.
6%, is driven by several key factors. These include the rising prevalence of chronic and lifestyle diseases, technological advancements in point-of-care (PoC) testing products, and growing patient awareness. Moreover, the market faces challenges such as high capital investments and a shortage of skilled laboratory technicians.
Opportunities lie in advancements in urine analyzers, particularly automated systems, and overcoming regulatory hurdles in the changing landscape of in vitro diagnostics (IVD). Major players like Siemens Healthineers, F. Hoffmann-La Roche Ltd.
, Cardinal Health, Abbott, and Danaher dominate the market with their extensive product portfolios and global presence..
